Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Commun ; 15(1): 2099, 2024 Mar 14.
Article in English | MEDLINE | ID: mdl-38485948

ABSTRACT

Filamentous fungi are critical in the transition to a more sustainable food system. While genetic modification of these organisms has promise for enhancing the nutritional value, sensory appeal, and scalability of fungal foods, genetic tools and demonstrated use cases for bioengineered food production by edible strains are lacking. Here, we develop a modular synthetic biology toolkit for Aspergillus oryzae, an edible fungus used in fermented foods, protein production, and meat alternatives. Our toolkit includes a CRISPR-Cas9 method for gene integration, neutral loci, and tunable promoters. We use these tools to elevate intracellular levels of the nutraceutical ergothioneine and the flavor-and color molecule heme in the edible biomass. The strain overproducing heme is red in color and is readily formulated into imitation meat patties with minimal processing. These findings highlight the promise of synthetic biology to enhance fungal foods and provide useful genetic tools for applications in food production and beyond.


Subject(s)
Aspergillus oryzae , Synthetic Biology , Synthetic Biology/methods , Gene Editing , Aspergillus oryzae/genetics , Aspergillus oryzae/metabolism , Mycelium/genetics , Heme/metabolism
2.
Elife ; 92020 02 18.
Article in English | MEDLINE | ID: mdl-32067637

ABSTRACT

Catechol dehydroxylation is a central chemical transformation in the gut microbial metabolism of plant- and host-derived small molecules. However, the molecular basis for this transformation and its distribution among gut microorganisms are poorly understood. Here, we characterize a molybdenum-dependent enzyme from the human gut bacterium Eggerthella lenta that dehydroxylates catecholamine neurotransmitters. Our findings suggest that this activity enables E. lenta to use dopamine as an electron acceptor. We also identify candidate dehydroxylases that metabolize additional host- and plant-derived catechols. These dehydroxylases belong to a distinct group of largely uncharacterized molybdenum-dependent enzymes that likely mediate primary and secondary metabolism in multiple environments. Finally, we observe catechol dehydroxylation in the gut microbiotas of diverse mammals, confirming the presence of this chemistry in habitats beyond the human gut. These results suggest that the chemical strategies that mediate metabolism and interactions in the human gut are relevant to a broad range of species and habitats.


Inside the human gut there are trillions of bacteria. These microbes are critical for breaking down and modifying molecules that the body consumes (such as nutrients and drugs) and produces (such as hormones). Although metabolizing these molecules is known to impact health and disease, little is known about the specific components, such as the genes and enzymes, involved in these reactions. A prominent microbial reaction in the gut metabolizes molecules by removing a hydroxyl group from an aromatic ring and replacing it with a hydrogen atom. This chemical reaction influences the fate of dietary compounds, clinically used drugs and chemicals which transmit signals between nerves (neurotransmitters). But even though this reaction was discovered over 50 years ago, it remained unknown which microbial enzymes are directly responsible for this metabolism. In 2019, researchers discovered the human gut bacteria Eggerthella lenta produces an enzyme named Dadh that can remove a hydroxyl group from the neurotransmitter dopamine. Now, Maini Rekdal et al. ­ including many of the researchers involved in the 2019 study ­ have used a range of different experiments to further characterize this enzyme and see if it can break down molecules other than dopamine. This revealed that Dadh specifically degrades dopamine, and this process promotes E. lenta growth. Next, Maini Rekdal et al. uncovered a group of enzymes that had similar characteristics to Dadh and could metabolize molecules other than dopamine, including molecules derived from plants and nutrients in food. These Dadh-like enzymes were found not only in the guts of humans, but in other organisms and environments, including the soil, ocean and plants. Plant-derived molecules are associated with human health, and the discovery of the enzymes that break down these products could provide new insights into the health effects of plant-based foods. In addition, the finding that gut bacteria harbor a dopamine metabolizing enzyme has implications for the interaction between the gut microbiome and the nervous system, which has been linked to human health and disease. These newly discovered enzymes are also involved in metabolic reactions outside the human body. Future work investigating the mechanisms and outputs of these reactions could improve current strategies for degrading pollutants and producing medically useful molecules.


Subject(s)
Catechols/metabolism , Diet , Enzymes/metabolism , Gastrointestinal Microbiome , Metalloproteins/metabolism , Humans
3.
Nat Microbiol ; 4(12): 2052-2063, 2019 12.
Article in English | MEDLINE | ID: mdl-31570867

ABSTRACT

Diet is a critical determinant of variation in gut microbial structure and function, outweighing even host genetics1-3. Numerous microbiome studies have compared diets with divergent ingredients1-5, but the everyday practice of cooking remains understudied. Here, we show that a plant diet served raw versus cooked reshapes the murine gut microbiome, with effects attributable to improvements in starch digestibility and degradation of plant-derived compounds. Shifts in the gut microbiota modulated host energy status, applied across multiple starch-rich plants, and were detectable in humans. Thus, diet-driven host-microbial interactions depend on the food as well as its form. Because cooking is human-specific, ubiquitous and ancient6,7, our results prompt the hypothesis that humans and our microbiomes co-evolved under unique cooking-related pressures.


Subject(s)
Bacteria/classification , Cooking , Diet , Food , Gastrointestinal Microbiome , Raw Foods/analysis , Adult , Animals , Feces/microbiology , Female , Genetic Variation , Germ-Free Life , Hot Temperature , Humans , Male , Metabolomics , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , RNA, Ribosomal, 16S/genetics , Transcriptome , Young Adult
4.
Science ; 364(6445)2019 06 14.
Article in English | MEDLINE | ID: mdl-31196984

ABSTRACT

The human gut microbiota metabolizes the Parkinson's disease medication Levodopa (l-dopa), potentially reducing drug availability and causing side effects. However, the organisms, genes, and enzymes responsible for this activity in patients and their susceptibility to inhibition by host-targeted drugs are unknown. Here, we describe an interspecies pathway for gut bacterial l-dopa metabolism. Conversion of l-dopa to dopamine by a pyridoxal phosphate-dependent tyrosine decarboxylase from Enterococcus faecalis is followed by transformation of dopamine to m-tyramine by a molybdenum-dependent dehydroxylase from Eggerthella lenta These enzymes predict drug metabolism in complex human gut microbiotas. Although a drug that targets host aromatic amino acid decarboxylase does not prevent gut microbial l-dopa decarboxylation, we identified a compound that inhibits this activity in Parkinson's patient microbiotas and increases l-dopa bioavailability in mice.


Subject(s)
Actinobacteria/enzymology , Antiparkinson Agents/metabolism , Bacterial Proteins/metabolism , Enterococcus faecalis/enzymology , Gastrointestinal Microbiome , Levodopa/metabolism , Tyrosine Decarboxylase/metabolism , Tyrosine/analogs & derivatives , Actinobacteria/drug effects , Actinobacteria/genetics , Animals , Antiparkinson Agents/administration & dosage , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/genetics , Decarboxylation/drug effects , Dopamine/metabolism , Enterococcus faecalis/drug effects , Enterococcus faecalis/genetics , Gastrointestinal Microbiome/genetics , Genome, Bacterial , HeLa Cells , Humans , Levodopa/administration & dosage , Male , Metabolic Networks and Pathways/drug effects , Mice, Inbred BALB C , Tyrosine/administration & dosage , Tyrosine/chemistry , Tyrosine/pharmacology , Tyrosine Decarboxylase/antagonists & inhibitors , Tyrosine Decarboxylase/genetics
5.
Science ; 356(6344)2017 06 23.
Article in English | MEDLINE | ID: mdl-28642381

ABSTRACT

The human gut microbiota makes key contributions to the metabolism of ingested compounds (xenobiotics), transforming hundreds of dietary components, industrial chemicals, and pharmaceuticals into metabolites with altered activities, toxicities, and lifetimes within the body. The chemistry of gut microbial xenobiotic metabolism is often distinct from that of host enzymes. Despite their important consequences for human biology, the gut microbes, genes, and enzymes involved in xenobiotic metabolism are poorly understood. Linking these microbial transformations to enzymes and elucidating their biological effects is undoubtedly challenging. However, recent studies demonstrate that integrating traditional and emerging technologies can enable progress toward this goal. Ultimately, a molecular understanding of gut microbial xenobiotic metabolism will guide personalized medicine and nutrition, inform toxicology risk assessment, and improve drug discovery and development.


Subject(s)
Bacteria/metabolism , Gastrointestinal Microbiome/physiology , Xenobiotics/metabolism , Bacteria/enzymology , Bacteria/genetics , Environmental Pollutants/chemistry , Environmental Pollutants/metabolism , Food , Humans , Pharmaceutical Preparations/chemistry , Pharmaceutical Preparations/metabolism , Research/trends , Xenobiotics/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...